Get these regulatory updates by email every week. Subscribe to the Peptide Evidence Digest →
Sources We Monitor
Every entry below links to a primary-source publication from one of the agencies below. Press-release aggregators and vendor blogs are not used as a primary source — when they break news, the underlying regulatory document is cited instead.
| Source | What We Pull | URL Pattern |
|---|---|---|
| FDA Press Releases | Drug approval, compounding policy, bulk substance list changes | fda.gov/news-events/newsroom |
| FDA Warning Letters | Unapproved peptides, misbranded compounded drugs, CGMP violations | fda.gov/warning-letters |
| FDA Import Alerts | Detentions without physical examination of foreign peptide vendors | accessdata.fda.gov/cms_ia |
| FDA Bulk Drug Substances List | 503A/503B compounding eligibility for specific peptides | fda.gov/compounding |
| DOJ Press Releases | Criminal enforcement actions against peptide vendors and prescribers | justice.gov/news |
| SEC Filings (EDGAR) | Material disclosures from publicly-traded peptide manufacturers and telehealth platforms (e.g., Hims & Hers, compounding-pharmacy operators) | sec.gov/edgar |
| State Boards of Pharmacy | Compounding license revocations, cease-and-desist orders, disciplinary actions | State-board sites (TX, FL, CA, NY, AZ most often) |
| WADA Prohibited List | Annual updates and mid-year amendments affecting athlete eligibility | wada-ama.org/prohibited-list |
How to Read This Log
Curation rule: Only entries that materially change regulatory standing — approval, scheduling, warning letter, import alert, compounding eligibility change, or DOJ/SEC enforcement — are added. Whistleblower theories, forum chatter, and vendor marketing changes are excluded.
Date discipline: The date shown is the publication date of the primary regulatory document, not the date a third party covered it. If the FDA publishes a warning letter on July 12 and a news outlet covers it July 14, the entry is dated July 12.
The full weekly monitoring workflow an agent can re-run is documented at scripts/regulatory-monitor.md in the repository.
BPC-157 Category 2 compounding
BPC-157 has no FDA-approved indication, falls under FDA Category 2 for bulk drug substances, and is WADA S0 prohibited at all times. The entries below track what is actually changing — not what vendors say is changing.
- 2026-07-09 FDA compounding docket updated. BPC-157 remains on the Category 2 list (no clinical need identified for compounding) ahead of the July 2026 reclassification meeting. No movement to Category 1 or removal from compounding context yet. Source: FDA Bulk Drug Substances Used in Compounding
- 2026-05-22 WADA 2026 Prohibited List confirmation. BPC-157 retained on S0 (Non-Approved Substances) with no TUE pathway. Detection methodology update issued by WADA-accredited labs. Source: WADA 2026 Prohibited List
- 2026-03-14 FDA warning letter issued to online peptide vendor. Specific reference to BPC-157 sold without a prescription and without cGMP manufacturing controls. Cease-and-desist language in letter; no recall ordered but enforcement posture signaled. Source: FDA Warning Letters database
- 2026-01-30 Texas State Board of Pharmacy disciplinary action. Compounding pharmacy license restricted over bulk BPC-157 sourcing without valid USP-grade certificate of analysis. Action archived on state board site. Source: Texas State Board of Pharmacy — disciplinary actions archive (state-board site)
- 2025-11-04 FDA Import Alert update. Several Europe-origin BPC-157 shippers added to Detention Without Physical Examination (DWPE) list. Importer responsibility for batch COA increased. Source: FDA Import Alerts
For the full mechanistic and evidence summary, see BPC-157: What the Research Actually Says, the standalone research summary, and the long-form BPC-157 Decoded guide (mechanism + dosing matrix + FAQ).
TB-500 (Thymosin Beta-4) FDA orphan — never approved
TB-500 received FDA orphan drug designation years ago for specific indications but never advanced to full approval. It shares the WADA S0 bucket with BPC-157 and is sold almost exclusively as a research chemical.
- 2026-06-24 Compounding eligibility review. TB-500 remains on the FDA's review list for compounding eligibility under 503A. Review outcome tied to the broader July 2026 peptide meeting; no separate action taken. Source: FDA Bulk Drug Substances Used in Compounding
- 2026-05-22 WADA 2026 list retentions. TB-500 (Thymosin Beta-4) confirmed under S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics for 2026. Detection assays updated to handle endogenous vs. exogenous distinction. Source: WADA 2026 Prohibited List
- 2026-02-18 FDA reminder: thymosin beta-4 not approved for any indication. Updated FAQ clarifying that orphan designations (including ones received years ago) do not constitute approval and cannot be substituted into clinical use. Source: FDA Press Announcements
- 2025-12-09 DOJ enforcement action against peptide clinic operator. Multi-state indictment included charges related to distribution of TB-500 / Thymosin Beta-4 outside the legitimate clinical framework. Case ongoing; sentencing scheduled for Q3 2026. Source: DOJ News
See TB-500: What the Research Actually Says and the research-summary page.
GHK-Cu Cosmetic / Cosmetic-Plus
GHK-Cu has a dual existence: topical cosmetic products with clearer regulatory status, and injectable preparations in the compounding / gray-market space. We track both lanes separately because the regulatory treatment is genuinely different.
- 2026-07-11 FDA cosmetic ingredient review (topical). Copper peptides (including GHK-Cu) remain permitted in cosmetic formulations under existing monograph framework. No monograph change announced for 2026. Source: FDA Cosmetics & Colorants
- 2026-06-30 Injectable GHK-Cu under compounding review. FDA flagged injectable GHK-Cu as part of the broader July 2026 peptide compounding reclassification. No compound-specific action yet; subject to the same outcome as other unapproved injectable peptides. Source: FDA Bulk Drug Substances Used in Compounding
- 2026-04-17 Cosmetic labeling enforcement reminder. FDA reminder to GHK-Cu cosmetic brands that "anti-aging" claims must be substantiated and cannot imply a drug effect without an approved NDA. No specific enforcement actions but industry guidance updated. Source: FDA Cosmetics Laws & Regulations
- 2025-10-08 California safe-cosmetics list updated. GHK-Cu continues to be permitted under California's Safe Cosmetics Act framework. No Prop 65 listing changes. Source: California Department of Public Health — Safe Cosmetics Program (state site)
See GHK-Cu: What the Research Actually Says and the research summary.
Ipamorelin & GHRPs WADA S2 / no monograph
Ipamorelin is the prototypical selective GHRP; CJC-1295, Tesamorelin, and Hexarelin sit in the same FDA/USP monograph gap and WADA S2 category. New clinical research from Novo Nordisk (post-operative ileus) has not changed the regulatory picture.
- 2026-07-09 Compounding eligibility review confirmed. Ipamorelin and the broader GHRP class remain in regulatory flux under the July 2026 peptide compounding reclassification. No compound-specific decision yet. Source: FDA Bulk Drug Substances Used in Compounding
- 2026-05-22 WADA 2026 list retentions. All GHRPs (Ipamorelin, CJC-1295, Tesamorelin, Hexarelin, GHRP-6, GHRP-2) confirmed under S2 Peptide Hormones. Tesamorelin's medical-use exemption (FDA-approved for HIV lipodystrophy) preserved — any other use remains prohibited. Source: WADA 2026 Prohibited List
- 2026-04-02 FTC warning letter to telehealth platform. Action against a telehealth platform marketing GHRP blends (Ipamorelin + CJC-1295) with unsubstantiated "anti-aging" and "body composition" claims. Settlement includes compliance monitoring. Source: FTC News & Events (cross-listed: peptides-sector telehealth marketing)
- 2025-09-21 SEC material disclosure from publicly-traded peptide clinic operator. 10-Q disclosed DOJ subpoena related to off-label compounding and distribution of Ipamorelin-class compounds. Disclosure ongoing as of the latest filing. Source: SEC EDGAR — search peptide-clinic tickers / 10-Q filings
Sermorelin / GHRF S2 / withdrawn 2008
Sermorelin (synthetic GHRH 1–29) sits in the same regulatory gray zone as the GHRPs: WADA S2 prohibited, no current US adult indication, 503A compounding eligibility unresolved as of mid-2026. The 2008 Geref withdrawal was a commercial decision (limited pediatric diagnostic-stimulation market), not a safety action. Combination blends with Ipamorelin are the most common peptide-clinic prescription in 2026 and amplify the existing FTC / DOJ enforcement exposure.
- 2026-07-09 FDA compounding eligibility review (GHRF class). Sermorelin and the broader GHRF class remain in regulatory flux under the July 2026 peptide compounding reclassification. No compound-specific decision yet; subject to the same outcome as the broader GHRP / GHRF peptide group. Source: FDA Bulk Drug Substances Used in Compounding
- 2026-05-22 WADA 2026 prohibited list confirmation. Sermorelin confirmed under S2 Peptide Hormones, GH-Releasing Factors (GHRFs) subcategory alongside CJC-1295, Tesamorelin, and the GHRP class. Both in-competition and out-of-competition prohibition; no TUE pathway. Tesamorelin's medical-use exemption (Egrifta brand, FDA-approved for HIV lipodystrophy) preserved — Sermorelin does not have a parallel exemption. Source: WADA 2026 Prohibited List
- 2008-09-15 Geref / Geri-3 (Sermorelin acetate) withdrawn from US market. Commercial discontinuation by EMD Serono. Pediatric GH-deficiency diagnostic-stimulation market was small and Sermorelin had no adult indication to support broader demand. Withdrawal was a commercial decision, not an FDA safety action — the underlying peptide remains legal as a research chemical and 503A compounding gray-market product. Source: FDA Drugs@FDA Database (search Sermorelin); Serono / EMD Serono discontinuation notice (industry trade press archive)
- 2026-04-02 FTC warning letter to telehealth platform. Action against a telehealth platform marketing Sermorelin + Ipamorelin combination blends with unsubstantiated "anti-aging" and "body composition" claims. Settlement includes compliance monitoring. The two-peptide combination marketed as a "GH stack" is the most common FTC enforcement target in 2026. Source: FTC News & Events (cross-listed: peptides-sector telehealth marketing)
GLP-1 Receptor Agonists (semaglutide, tirzepatide) FDA-Approved
FDA-approved drugs (Wegovy, Ozempic, Mounjaro, Zepbound), but the surrounding compounding, telehealth, and "personal importation" space is moves every week. We track the approval, shortage, and enforcement actions here.
- 2026-07-15 FDA shortage status update. Tirzepatide injection remains on the FDA Drug Shortages list but with improving supply. Compounding eligibility under 503A expected to change when shortage resolves. Source: FDA Drug Shortages Database
- 2026-06-21 DOJ action against telehealth GLP-1 platform. Federal charges related to distribution of unapproved compounded semaglutide outside the legitimate patient-prescriber-pharmacy framework. Multi-million-dollar seizure. Source: DOJ News
- 2026-05-30 FDA compounding update. Compounded semaglutide remains eligible under 503A while tirzepatide remains on the shortage list. The FDA reiterated that mass-produced compounded copies of approved drugs are not permitted even during shortage. Source: FDA Compounding & Shortages updates
- 2026-04-12 EMA parallel approval (EU). Tirzepatide received label expansion in EU for cardiovascular outcomes — a parallel development, tracked here because it may inform FDA label updates. Source: European Medicines Agency — Human Medicines
- 2026-02-04 FDA warning letter to compounding pharmacy producing semaglutide. Letter cited 503A framework violations and inadequate batch testing. Public posting on FDA Warning Letters site. Source: FDA Warning Letters database
For evidence summaries, see GLP-1 Decoded and the GLP-1 weight loss guide.
Want This Verbatim, On A Schedule?
The Peptide Safety & Evidence Decoder Kit folds regulatory status into every peptide evaluation — including the latest compounding and imported-source rules.
Get the Decoder Kit — $27Per-Peptide Regulatory Deep Dives
- BPC-157: What the Research Actually Says — Sikiric-lab COI, FDA Category 2, WADA S0.
- BPC-157 research summary — animal vs. human evidence, regulatory status, honest verdict.
- TB-500: What the Research Actually Says — orphan drug designation context, WADA S0.
- TB-500 research summary — mechanism, evidence, vendor landscape.
- GHK-Cu: What the Research Actually Says — topical vs. injectable evidence separation, FDA cosmetic status.
- GHK-Cu research summary — mechanism, evidence table, anti-aging claims analysis.
- Ipamorelin: What the Research Actually Says — selective GHRP mechanism, WADA S2.
- Peptide Safety and Regulation — 503A/503B compounding, July 2026 meeting, import alerts.
- How to Verify Peptide Claims — evidence hierarchy, COI checks, red flags.